UNSPSC 51332703: Clozapine

This classification denotes a 5-ht3 receptor antagonist and antipsychotic agent with the molecular formula C18H19ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J60AR2IKIC, chemically known as 8-chloro-11-(4-methyl-1-piperazinyl)-5h-dibenzo(b,e)(1,4)diazepine but generally known as clozapine, which bears US NIH Compound Identifier 2818. European Medicines Agency schedules Clozapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06787MIG.

UNSPSC 51332703 Clozapine is a Commodity code covering pharmaceutical products, but recent state and local procurement activity under this code does not focus on clozapine specifically. Instead, issuing bodies are soliciting naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription program services. The work ranges from procurement of finished pharmaceutical inventory for community health and pharmacy benefit programs to exploratory vendor-capability assessments for alternative distribution models that bypass traditional pharmacy benefit managers and wholesalers. State and local buyers using this code include individual counties (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participant states). The predominant issuing body in recent activity is MMCAP, a cooperative vehicle that consolidates purchasing across multiple state and local facilities.

Procurement activity appears concentrated in Florida, Texas, Minnesota, and Oregon. Recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due Jul 26, 2026), with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term plus one-year renewal option; the Texas Health and Human Services Commission's Request for Information (RFI) on direct-to-manufacturer prescription programs (posted Apr 3, 2026), which sought vendor capabilities for implementing Therapeutic Pharmacy Initiative programs outside traditional PBM and wholesaler channels; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due Mar 26, 2026, effective Jul 1, 2026 with a two-year term), which requires vendors to supply through three authorized wholesalers with pricing weighted 75 percent and EDI capability at 5 percent. Vendors responding to these opportunities must meet cGMP and Drug Supply Chain Security Act compliance, carry specified insurance minimums, and in the case of MMCAP, maintain relationships with at least two of three authorized wholesale distributors.